跳至主要内容
临床试验/ACTRN12606000129583
ACTRN12606000129583尚未招募4 期

A randomised controlled trial to assess the antiplatelet effect of a 600mg (single-dose) and 1,200mg (split-dose) loading dose of clopidogrel and the impact of verapamil, a potent CYP3A4 inhibitor, on the incidence of clopidogrel resistance defined by the VerifyNow? (Accumetrics Ltd) P2Y12 platelet function analyzer in patients with coronary disease.

Auckland City Hospital.0 个研究点目标入组 120 人开始时间: 2006年4月7日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
o limit 至 o limit(—)
性别
All

入选标准

  • 1. Signed informed consent2. All-comers (male and female of any age) with coronary disease on aspirin scheduled for elective PCI

排除标准

  • 1. A bleeding or platelet disorder2. Previous gastrointestinal bleeding or gastric ulcer/duodenal ulcer/gastritis3. Sensitivity/allergy to aspirin or clopidogrel or verapamil4. Renal failure Cr >0.12mmol/L 5. Anaemia Hb <115mg/dL6. Medication inhibiting CYP3A4.

研究者

相似试验